SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC).
GSK's chief executive, Luke Miels. Shares in GSK fell today on a 2% decline in vaccine sales in the third quarter, although demand for other medicines was strong and there are signs that the revamp of the business under new management…
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Forlong Biotechnology Announces First Patient…
LANCASTER, Pa. — They saved Petunia first. She was the second cow. Her brother Louie had died within hours of his birth. But over two harrowing, sleepless nights, the three researchers kept Petunia alive to wheel her from the barn to…
A patient who received Bristol Myers’ zola-cell died 44 days later. Elswehere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill. Today, a brief rundown of news involving Bristol Myers Squibb and the U.S.
Pricing pressures, combined with a volatile U.S. regulatory and government funding environment, have increasingly steered biotechs and pharma to pursue clinical studies in Australia, CROs told BioSpace. Recent Australian government incentives to promote life sciences in states such as Queensland and…
Reforms to the regulatory framework for clinical research in the UK are starting to deliver, with delivery times slashed by 35%, according to new government figures. According to the Department of Health and Social Care (DHSC) and the Office of Life…
By John Wilkerson and Damian Garde WASHINGTON — The Trump administration late on Thursday proposed a rule that would severely restrict future U.S. investment in the Chinese biotech sector but still allow American drugmakers to buy the rights to medicines invented…
These emerging dynamics were discussed in recent analysis, which revealed the average number of studies greenlit at EU/EEA level has fallen 13.5% a year since 2013, excluding an uptick during the COVID-19 pandemic. They also suggested “the post-pandemic contraction in biopharma…
Meghana Keshavan is a biotech correspondent at STAT and co-writer of The Readout newsletter. She joined STAT in 2016. She has written about the life sciences industry for more than a decade. Before that, she worked for news outlets like Thomson…
China's biotech industry: its innovative drugmakers, out-licensing deals with Western pharma, US-China tensions and the BIOSECURE Act.
An article joins this feed when it matches these terms. Each one is also a search of its own.